Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. (HKG: 6990)

Market Cap	36.20B
Revenue (ttm)	2.02B
Net Income (ttm)	-200.51M
Shares Out	227.27M
EPS (ttm)	-0.92
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	7,318
Average Volume	179,175
Open	159.30
Previous Close	160.30
Day's Range	159.30 - 159.30
52-Week Range	63.65 - 223.80
Beta	n/a
RSI	42.52
Earnings Date	Mar 26, 2025

About Sichuan Kelun-Biotech Biopharmaceutical

Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd., a biopharmaceutical company, engages in the research and development, manufacturing, and commercialization of novel drugs to address unmet medical needs in the People’s Republic of China and internationally. The company is developing various drugs to treat breast, non-small cell lung, and gastrointestinal cancer, as well as non-oncology diseases. Its product pipeline includes oncology drug candidates, such as SKB264 (sacituzumab tirumotecan), A166 (trastuzumab botidotin), SKB315, A167 (tagitanl...

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 2016
• Employees: 1,477
• Stock Exchange: Hong Kong Stock Exchange
• Ticker Symbol: 6990

Financial Performance

In 2023, Sichuan Kelun-Biotech Biopharmaceutical's revenue was 1.54 billion, an increase of 91.62% compared to the previous year's 803.93 million. Losses were -522.21 million, -4.72% less than in 2022.

Financial numbers in CNY